Adjacent Evidence Brief: Telomere Cancer Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Add a clearly scoped Key Findings section that names the 2–3 most-supported outcome-specific signals (e.g., shorter LTL associated with worse CRC survival per Sarkar 2026; MR-supported long-LTL → increased risk for several neoplasms per Chen 2023) with their source citations, rather than only a methodological header.
2. Reconcile the five-domain vs. seven-slice source stratification: either consolidate to five outcome domains matching the abstract, or correct the abstract to state seven slices with their n counts.
3. Recompute and report the actual MR/ causal-risk source count from the bundle (Wan 2023, Song 2022, Chen 2023, Markozannes 2022, plus any others) rather than asserting an unsupported 7/25 figure.
4. Reclassify Jaeger 2024 as direct interventional evidence (RCT with TL endpoint) and adjust the direct-evidence count and the '0/25 direct sources' statement in Gaps Identified accordingly.
5. Surface the direction-coded findings for at least the top-cited sources in each outcome class (not just receipt-level null/unclear) so that 'significant source statistic' rows are interpretable.

Major issues

• Search summary is internally contradictory: the manuscript states 25 admitted sources stratified into five domains, but the Evidence Landscape table only lists 7 outcome-class slices whose n-sums (17+3+1+1+1+1+1=25) cross-count overlapping sources rather than independent strata, and the five-domain claim in the abstract is never reconciled with this seven-slice layout.
• The Evidence-honesty note and conclusion assert no direct interventional hard-endpoint evidence, yet Jaeger 2024 is an RCT of an Astragalus-based supplement with telomere-length endpoint and is classified as 'indirect' rather than direct; this misclassification understates the corpus and inflates the 'hypothesis-only' framing.
• The conclusion claims causal-risk and Mendelian-randomization evidence is 7/25 (dominant), but only Chen 2023 (review of MR studies) and Markozannes 2022 (review of MR studies) are explicitly MR reviews in the bundle; Wan 2023 and Song 2022 are individual MR studies, and the 7/25 figure is not traceable to the source bundle.
• Key Findings section is effectively empty of substantive content beyond a methodological note, so the synthesis weight must be inferred from Conclusion alone, weakening auditability.

Minor issues

• Several source rows report effect_direction='unclear' despite significant p-values; the manuscript should make explicit which direction-coded claims are positive vs. null (e.g., Brouwers 2016 coded positive but p=0.88 is reported for LTL change, which is non-significant).
• 'Claims=473' for contextual_other with only 4 source-level examples shown suggests the underlying extraction is not surfaced in prose; this makes the reader unable to audit the headline number.
• Multiple DOIs carry 2026 publication years (Li, Davidson-Swinton, Liu, Brown, Genetta, Aierken, Afolabi, Cheng, Gil-Korilis, Langsenlehner, Sarkar, Alqaisi) — likely forthcoming/in-press; this is acceptable but should be flagged.
• Domain slug is 'longevity' while the synthesis is about telomere cancer effects; the slug-field inconsistency should be corrected.

Reviewer note

The manuscript is an AI-assisted rapid evidence brief on telomere cancer effects with 25 retained sources, explicit search scope across 12 databases, deterministic protocol, and a clearly bounded conclusion that no direct interventional hard-endpoint evidence supports broad clinical or policy claims. The search summary is auditable and the limitations section is specific and material (evidence-role imbalance, endpoint heterogeneity, numeric exclusion). Source grounding is generally good — DOIs are valid, citations match bundle entries, and direction codes are present. However, several issues prevent acceptance: (1) the abstract claims five stratified domains while the Evidence Landscape shows seven outcome-class slices whose n-sums double-count sources; (2) the direct-evidence count ('0/25 admitted') is contradicted by the presence of Jaeger 2024, an RCT with a telomere-length endpoint, which is misclassified as indirect; (3) the 7/25 MR/causal-risk figure asserted in the Conclusion cannot be traced to the visible source bundle, which contains only Chen 2023 and Markozannes 2022 as MR reviews and Wan 2023 and Song 2022 as individual MR studies; (4) the Key Findings section is effectively empty, leaving the Conclusion to do all synthetic work without auditable intermediate steps. The overall claim pattern — context-dependent associations, no clinical actionability — is appropriately hedged and proportionate to the indirect/observational/MR evidence, so this is a revise rather than a reject: bounded edits that reconcile the stratification scheme, correct the direct-evidence count, trace the MR proportion, and populate Key Findings with source-anchored signals would bring the manuscript to accept-quality.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis